By Val Brickates Kennedy Shares of partners Elan Corp. (ELN) and Wyeth (WYE) both moved lower Thursday after the companies said they were discontinuing part of a Phase III clinical trial for their Alzheimer's treatment bapineuzumab over safety issues.
Sourse: More Info
Thursday, April 2, 2009
Elan, Wyeth Slide On Alzheimer's Drug Setback
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment